Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Leases (2020 - 2025)

Barinthus Biotherapeutics' Current Leases history spans 6 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Current Leases rose 5.36% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 5.36%, while the annual FY2025 figure was $2.0 million, 5.36% up from the prior year.
  • Current Leases reached $2.0 million in Q4 2025 per BRNS's latest filing, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.0 million in Q2 2025 to a low of $186000.0 in Q3 2022.
  • Average Current Leases over 5 years is $1.2 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Current Leases: crashed 57.24% in 2022, then skyrocketed 706.99% in 2023.
  • A 5-year view of Current Leases shows it stood at $523000.0 in 2021, then dropped by 17.21% to $433000.0 in 2022, then skyrocketed by 312.24% to $1.8 million in 2023, then increased by 7.56% to $1.9 million in 2024, then rose by 5.36% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Current Leases are $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025).